Faron on linked in11 Dec 2025 13:25
This year’s ASH meeting underscored two themes: the significant unmet need in high-risk MDS and the rapid evolution of AML treatment.
While progress in lower-risk MDS and targeted AML regimens is encouraging, the challenge of durable outcomes in HR-MDS remains critical.
From genomic breakthroughs to targeted therapies, immunotherapies, and CAR‑T, this year’s meeting reinforced how far we have come and the urgent work that still lies ahead.
Key takeaways:
💎 HR‑MDS unmet need persists: The Phase 3 VERONA trial (venetoclax + azacitidine) did not improve OS vs azacitidine alone, despite subgroup trends highlighting the need for novel mechanisms.
💎 Bexmarilimab + azacitidine stood out as the only non‑Venetoclax oral presentation in the MDS treatment advances session:
💡 mOS 14.5 months in r/r HR‑MDS
💡 70% CR in frontline TP53‑mutated disease; 50% proceeded to transplant
💡 57% transfusion independence in frontline patients
👉 Watch a short ASCO Post Newsreel on these results: http://bit.ly/4aIp2yw
💎 Menin inhibitors are emerging as the “new kid on the block” in AML, with ~62% CRc rates in treatment‑naïve patients.
💎 Aza‑Ven vs 7+3: A less intensive regimen challenged a 50‑year standard in AML induction - better EFS, higher ORR, fewer grade 3 events, and lower early mortality.
💎 Depth matters: Composite CR (cCR) and MRD negativity are becoming critical metrics for durability, alongside SCT bridging and transfusion independence.
The next frontier: Precision, innovation, and mechanisms that restore marrow function - not just cytoreduction.
Sign In
Follow the stocks
